To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.

Patients will attend up to 9 study visits over a period of up to 28 days.

Inclusion Criteria:

1. Age ≥ 18 years and ≤ 75 years at the time of the assessment

2. Able and willing to understand the study, adhere to all study procedures, and provide written informed consent

3. Diagnosis of COVID-19 disease:

   1. If symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with FDA-cleared molecular diagnostic assay positive for SARS-CoV-2 within 72 hours from swab to the time of commencing informed consent:
   2. If asymptomatic, initial diagnosis of SARS-CoV-2 infection with positive FDA-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent

Exclusion Criteria:

1. Patients who are hospitalized for inpatient treatment or currently being evaluated for potential hospitalization at the time of initiation of informed consent

2. Patients with a known allergy to Peginterferon Lambda-1a or any component thereof

3. Display symptoms of respiratory distress (Respiratory rate >20, room air oxygen saturation of <94%.)

4. Participation in a clinical trial with or use of any investigational agent within 30 days before screening

5. Treatment with interferons (IFN) within 12 months before screening

6. Previous use of Peginterferon Lambda-1a

7. History or evidence of any intolerance or hypersensitivity to IFNs or other substances contained in the study medication.

8. Female patients who are pregnant or breastfeeding. Male patients must confirm that their female sexual partners are not pregnant.

9. Current or previous history of decompensated liver disease (Child-Pugh Class B or C) or hepatocellular carcinoma

10. Co-infected with human immunodeficiency virus (HIV)

11. Significant abnormal laboratory test results at screening.

12. Other significant medical condition that may require intervention during the study

13. Concurrent use of any of the following medications:

    1. Therapy with an immunomodulatory agent
    2. Current use of heparin or Coumadin
    3. Received blood products within 30 days before study randomization
    4. Use of hematologic growth factors within 30 days before study randomization
    5. Systemic antibiotics, antifungals, or antivirals for treatment of active infection within 24 hours before study randomization
    6. Any prescription or herbal product that is not approved by the investigator
    7. Long-term treatment (> 2 weeks) with agents that have a high risk for nephrotoxicity or hepatotoxicity unless it is approved by the medical monitor
    8. Receipt of systemic immunosuppressive therapy within 3 months before screening

Sharing of generated and analyzed datasets.

The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository

Full access

11 months

Single-blind study in which only patients are blinded.